D.E. Shaw & Co’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

D.E. Shaw & Co’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-32,782	Closed	-$167K	–	6034
2022 Q1	$167K	Sell	32,782 -117,880	-78%	-$741K	﹤0.01%	4911
2021 Q4	$848K	Sell	150,662 -149,493	-50%	-$1.27M	﹤0.01%	4067
2021 Q3	$3.33M	Sell	300,155 -2,414	-0.8%	-$30.3K	﹤0.01%	2519
2021 Q2	$5.13M	Buy	302,569 +254,518	+530%	+$4.82M	﹤0.01%	2014
2021 Q1	$1.26M	Buy	48,051 +35,084	+271%	+$1.59M	﹤0.01%	2928
2020 Q4	$469K	Buy	+12,967	New	+$469K	﹤0.01%	3420
2020 Q3	–	Sell	-755	Closed	-$32K	–	4299
2020 Q2	$32K	Buy	+755	New	+$50.9K	﹤0.01%	3936

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

D.E. Shaw & Co's EVFM Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 32,782 shares — an estimated $167K sold.

D.E. Shaw & Co first reported a position in EVFM in Q2 2020 and held it in 7 quarters. The position peaked at $5.13M in Q2 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

D.E. Shaw & Co reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
D.E. Shaw & Co sold 32,782 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $167K.
D.E. Shaw & Co first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
D.E. Shaw & Co's Evofem Biosciences, Inc. Common Stock position peaked at $5.13M in Q2 2021.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.